User profiles for John Seibyl
John P. SeibylInstitute for Neurodegenerative Disorders Verified email at indd.org Cited by 40251 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses
Background: To characterize further behavioral, cognitive, neuroendocrine, and physiological
effects of subanesthetic doses of ketamine hydrochloride in healthy human subjects. …
effects of subanesthetic doses of ketamine hydrochloride in healthy human subjects. …
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
…, SS Zoghbi, RM Baldwin, JP Seibyl… - Proceedings of the …, 1996 - National Acad Sciences
The dopamine hypothesis of schizophrenia proposes that hyperactivity of dopaminergic
transmission is associated with this illness, but direct observation of abnormalities of dopamine …
transmission is associated with this illness, but direct observation of abnormalities of dopamine …
[HTML][HTML] MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder
Objective Studies in nonhuman primates suggest that high levels of cortisol associated with
stress have neurotoxic effects on the hippocampus, a brain structure involved in memory. …
stress have neurotoxic effects on the hippocampus, a brain structure involved in memory. …
The Parkinson progression marker initiative (PPMI)
…, C Meunier, A Rudolph, C Casaceli, J Seibyl… - Progress in …, 2011 - Elsevier
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to improve …
international, multi-center study designed to identify PD progression biomarkers both to improve …
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort
OBJECTIVE: The authors previously observed an increase in striatal dopamine transmission
following amphetamine challenge in 15 untreated patients with schizophrenia compared to …
following amphetamine challenge in 15 untreated patients with schizophrenia compared to …
[HTML][HTML] CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER …
Introduction We studied whether fully automated Elecsys cerebrospinal fluid (CSF)
immunoassay results were concordant with positron emission tomography (PET) and predicted …
immunoassay results were concordant with positron emission tomography (PET) and predicted …
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Objective To compare initial treatment with pramipexole vs levodopa in early Parkinson
disease, followed by levodopa supplementation, with respect to the development of …
disease, followed by levodopa supplementation, with respect to the development of …
Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale
…, L Brenner, J Erdos, DC d'Souza, JP Seibyl… - Schizophrenia …, 2010 - Elsevier
BACKGROUND: Nonlocalizing neurologic deficits detectable by clinical evaluation–“soft
signs”–are a robust finding in patients diagnosed with schizophrenia, but their conceptual and …
signs”–are a robust finding in patients diagnosed with schizophrenia, but their conceptual and …
[HTML][HTML] Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon …
Background: Prior research has suggested reductions in the density of serotonin transporter
(SERT) binding sites in blood platelets and post-mortem brain tissue of depressed patients. …
(SERT) binding sites in blood platelets and post-mortem brain tissue of depressed patients. …
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
…, F Hiemeyer, SM Wittemer-Rump, J Seibyl… - The Lancet …, 2011 - thelancet.com
Background Imaging with amyloid-β PET can potentially aid the early and accurate
diagnosis of Alzheimer's disease. Florbetaben ( 18 F) is a promising 18 F-labelled amyloid-β-…
diagnosis of Alzheimer's disease. Florbetaben ( 18 F) is a promising 18 F-labelled amyloid-β-…